09/18/2012 - 3:43pm

The saturated oral care segment is benefiting — and is poised to continue to benefit — from toothpastes that promise to deliver value-added benefits.


09/18/2012 - 3:43pm

Judging from the number of dietary supplement companies that are being snatched up by heavy-hitting suppliers in the over-the-counter space, the 5% uptick in supplement sales for the 52 weeks ended Aug. 12 is one trend that stands to continue.

09/18/2012 - 3:43pm

“Life…supplemented” last month launched a resource app for iPhones and iPads. DSN sat down with Judy Blatman, SVP communications for the Council for Responsible Nutrition, to get the details on the launch.


09/18/2012 - 3:43pm

The overall foot care category was relatively flat — down 0.9% — with $587.2 million in sales for the 52 weeks ended Aug. 12 across food, drug and mass (excluding Walmart), according to SymphonyIRI Group data. However, almost 2-out-of-3 foot care products sold are insoles, which bodes well for sales 
going forward. 


09/18/2012 - 3:43pm

Earlier this summer Hyland’s introduced its Leg Cramps Ointment to complement its line of homeopathic Leg Cramps tablets. Expect the leg cramp market to grow.

09/18/2012 - 3:43pm

Similasan is one homeopathic company making a move into pediatric cough/cold.

09/18/2012 - 3:43pm

Over the last few years of DSN’s coverage of the impending patent cliff and how it would affect the generic drug industry, IMS Health VP industry relations Doug Long predicted that the gradual commoditization of primary care drugs — long the lifeblood of generic drug makers — would lead to consolidation of the industry.


09/18/2012 - 3:43pm

It’s a little hard not to say “Oh, how the mighty have fallen” when a retailer announces that it will give away for free what was once the world’s top-selling drug. But for retailers, it also makes good business sense.


09/18/2012 - 3:42pm

For branded drug makers, the pharmaceutical patent cliff has never loomed higher or steeper. The exposure of so many of the world’s biggest-selling medicines to generic competition for the first time is redefining the pricing model for many of the most widely prescribed classes of pharmaceuticals.